Stroke Circulatory System Stroke
Conditions
Interventions
A single oral dose of 100,000 U ergocalciferol (vitamin D) or placebo.
Sponsors
University of Dundee (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of completed stroke (ischaemic or haemorrhagic) 2. Serum 25-hydroxy vitamin D level less than 50 nmol/L
Exclusion criteria
Exclusion criteria: 1. Hyper- or hypocalcaemia 2. Metastatic malignancy 3. Liver function tests over three times limit of normal 4. Estimated glomerular filtration rate (GFR) less than 40 ml/min 5. Previous clinical diagnosis of osteomalacia 6. Taking vitamin D preparations 7. Unable to give written informed consent 8. Unable to swallow tablets orally 9. Atrial fibrilation (to provide a more homogeneous aetiology)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure (seated office and 24 hour measurements) (added 26/02/2018: measured using a blood pressure cuff) at baseline, 8 and 16 weeks after vitamin D administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures (as of 26/02/2018): All outcomes are measured at baseline, and 8 and 16 weeks after vitamin D administration: 1. Endothelial function of the artery in the arm is measured using ultrasound following an inflated blood pressure cuff 2. B-type natriuretic peptide is measured from a blood sample 3. Heart rate variability is measured using a 24 hour ECG 4. Vitamin D deficiency is measured using 25OHD Previous secondary outcome measures; The secondary outcomes will also be measured at baseline and then at 8 and 16 weeks after vitamin D administration. 1. Endothelial function 2. B-type natriuretic peptide 3. Heart rate variability | — |
Countries
United Kingdom
Outcome results
None listed